Augmedix, Inc.
111 Sutter Street, Suite 1300
San Francisco, California 94104
May 3, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: Janice Adeloye
Re: Augmedix, Inc.
Registration Statement on Form S-3
(File No. 333-264337)
Request for Acceleration
Dear Ms. Adeloye:
Pursuant to Rule 461 of the General Rules and Regulations of the Securities and Exchange Commission promulgated under the Securities Act of 1933, as amended, Augmedix, Inc. hereby requests that the effective date of the above-captioned Registration Statement on Form S-3, as amended, be accelerated to 4:00 p.m., Eastern Time, on May 6, 2022, or as soon as practicable thereafter.
Please contact John Rafferty of Morrison & Foerster LLP via telephone at (415) 268-6897 or via e-mail at JRafferty@mofo.com with any questions you may have. In addition, please notify Mr. Rafferty when this request for acceleration has been granted.
| Sincerely, | ||
| Augmedix, Inc. | ||
| /s/ Emmanuel Krakaris | ||
| Name: | Emmanuel Krakaris | |
| Title: | Chief Executive Officer | |
cc: Paul Ginocchio, Chief Financial Officer
John Rafferty, Esq.
John Owen, Esq.
